Navigation Links
Misonix Reports Financial Results for First Half of Fiscal 2013
Date:2/7/2013

cts, BoneScalpel, SonicOne and SonaStar revenue increased 46% for the six months ended December 31, 2012. We are pleased with that performance."

"Bottom-line results were impacted by an unfavorable product mix of low and high margin product deliveries, additional headcount as we continue to invest in our sales and marketing team, and increased selling expenses as more distributors become engaged in selling our products. We expect that these impacts will be offset as we continue to grow revenues in the coming quarters."

Mr. McManus concluded, "The financial base of the Company continues to be strong with $6.9 million in cash and equivalents and zero long-term debt. We continue to make progress in expanding our business both domestically and internationally. While we are still in the early stages of executing on our plan as a focused medical device company, we are pleased with the progress made to date."

Conference Call:Michael A. McManus Jr., President and Chief Executive Officer, and Richard Zaremba, Senior Vice President and Chief Financial Officer, will host a conference call Thursday, February 7, 2013 at 4:30 pm ET to discuss the financial results of the first half of fiscal 2013.

Shareholders and other interested parties can access the conference call by dialing (877) 317-6789 or (412) 317-6789 or can listen via a live Internet webcast, which is available in the Investor Relations section of the Company's website at www.misonix.com.

A teleconference replay of the call will be available for three days at (877) 344-7529 or (412) 317-0088, confirmation # 10024916. A webcast replay will be available in the Investor Relations section of the Company's website at www.misonix.com for 30 days.

About Misonix:Misonix, Inc. designs, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis
'/>"/>

SOURCE Misonix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Misonix Presents at MicroCapClub Invitational
2. Misonix Terminates Distribution Agreement With Aesculap
3. Misonix Reports Strong Revenue Increases for the First Quarter of Fiscal 2013
4. Misonix Reports Strong Revenue Increases for the Three Months and Full-Year Ended June 30, 2012
5. Misonix Product Featured At Neurosurgery Congress
6. Misonix Adds 6 Spine Sales Agencies In The U.S.
7. Misonix Attends International Meeting On Advanced Spine Techniques (IMAST) - Introduces New Product
8. Misonix Inks New Distribution Agreement For Croatia And Slovenia
9. Misonix And Soelim Create New Distribution Alliance For South Korea
10. Misonix Participates In Cleveland Spine Review
11. Misonix Adds Industry Veteran To Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)...  Sanofi (EURONEXT: SAN and NYSE: SNY ) ... , examining the selective JAK2 inhibitor SAR302503 for ... groups. The primary endpoint assessed the proportion of patients ... reported in previous trials, the most common adverse events ... be presented at an upcoming medical congress. ...
(Date:5/16/2013)... ZURICH , May 17, 2013 ... Research (A*STAR) and Switzerland,s Cytos Biotechnology ... dosed in a Phase 1 clinical trial with their H1N1 ... particle (VLP) technology. In this first Phase 1 clinical trial, ... its potential to protect against H1N1 influenza infection will be ...
(Date:5/16/2013)... N.C. , May 16, 2013  Today, the ... North Carolina House of Representatives recently approved ... for chemotherapy from charging patients higher out-of-pocket fees for ... formularies, many of which have more severe side-effects. However, ... limit of $300, which will continue to be a ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
... III study will evaluate effects of otelixizumab, an investigational anti-CD3 ... ... secretion, CAMBRIDGE, Mass., April 9, 2008 ... development of novel,therapies for immune-mediated diseases, today announced that it is,proceeding ...
... Calif., April 9, 2008 ,Poniard Pharmaceuticals, Inc. (Nasdaq: ... today announced that data from a Phase 2 ... patients with small,cell lung cancer (SCLC) will be ... Lung Cancer Conference in Geneva, Switzerland. The presentation ...
Cached Medicine Technology:Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting 2Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting 3Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting 4Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference 2Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference 3
(Date:5/19/2013)... The Pradaxa lawyers at Bernstein Liebhard ... convened for hundreds of Pradaxa bleeding lawsuits ... U.S. District Court, Southern District of Illinois. According ... 14th, the Conference addressed the status of depositions and ... Conference that Defendants submitted a list of early trial ...
(Date:5/19/2013)... 19, 2013 Farming methods have changed ... the ground 10,000 years ago. Most recently, the Green ... by using genetically engineered seeds and by applying chemical ... backlash to these techniques due to the adverse environmental ... a corresponding surge in interest in organic, sustainable farming ...
(Date:5/19/2013)... WA (PRWEB) May 19, 2013 The Fat ... weight loss secrets that help people get in ... gender, and body shape. The program also is a natural ... diet plans. Besides, the author of this fat loss diet ... transformation program, which can help people keep body fat off ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Yeast infections are ... appear in sensitive areas of the human body. A new ... This new formula provides a unique method of application to ... spray solution is now provided to men and women searching ... naturally absorbed in the body through food and is stored ...
(Date:5/19/2013)... 19, 2013 Exciting new Skin Brushes ... reintroducing a great practice known through the ages but ... as dry body brushing, has so many benefits for ... Sublime Beauty®. "We love that circulation and lymphatic systems ... organ, the skin, is supported through Skin Brushing." , ...
Breaking Medicine News(10 mins):Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 2Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 3Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 2Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 3Health News:Weight Loss Secrets | How “The Fat Loss Code” Helps People Gain A Healthy Life And Get In Shape - Health Review 2Health News:A Safe & Homeopathic Yeast Infection Relief by Yeastrol Now Available at HealthCareSupplementz.com with Massive Discount 2Health News:Exciting New Skin Brushes at Sublime Beauty® Bring Health and Beauty Benefits; Celebrities and Models Know the Secret 2
... at Weill Cornell Medical College could prove a potent weapon ... called SS31, is able to cross the blood-brain barrier and ... damage. ,"In our experiments, we found that exposing ... a much smaller area of brain tissue being affected," says ...
... (WHO) has approved four new drugs manufactured by the Macleods ... one of the four would be used against some strains ... of these four medicines will reinforce efforts to scale up ... in a statement. ,The medicines are the first ...
... out that organically grown kiwifruit has more health benefits ... This study is reported in the SCI’s magazine Chemistry ... in January that consuming organic fruits was just a ... by Drs. Maria Amodio and Adel Kader, showed that ...
... up 21 community medical centres in 20 provinces. This is ... run by the state, many of which are overflowing with ... is also intended to bring improvements to medical services in ... has said that 13 centres will be built in the ...
... independent survey which was conducted in all mental health ... continue to remain in mixed wards//. This is much ... in 99% of hospitals. ,The healthcare commission ... sleeping accommodation or bathrooms with the opposite sex. This ...
... fatty acids docosahexaenoic acid (DHA) successfully reduced diastolic blood ... up previous results with higher doses. // ,"A ... likely to be of clinical significance with regard to ... lead author Hannah Theobald from King's College London. ...
Cached Medicine News:Health News:Antioxidant Molecule Could Help Minimize Stroke-Linked Brain Damage 2Health News:Indian Pharma Authorized to Market New Anti-TB Drugs 2Health News:organic kiwifruits promote health 2Health News:Hospital Projects to Take the Weight Off Overcrowded Ones 2Health News:Low-dose Omega-3 Linked to Lower Blood Pressure 2
... its wide orifice tip, the Finntip Wide ... suspensions and macromolecules like genomic DNA. This ... cell fragmentation. It is excellent for use ... model, the inside diameter of the orifice ...
... Packed conveniently in plastic-wrapped racks of 96 ... useno need to autoclave. Sterilized Diamond Tips ... sterilization and are delivered with a certificate ... Sterilized Diamond Tips are certified free of ...
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
This large orifice 1000 ul tips is the large volume alternative to MBP's 200G tip. Pipet fragile cells, viscous samples and genomic DNA with ease....
Medicine Products: